Our vision is to help save lives by ensuring antibiotics continue to be an effective treatment for future generations. We develop and deliver preferred solutions for healthcare providers, enabling them to accurately diagnose and treat infectious disease in the shortest possible time.

Q-linea was founded in Uppsala, Sweden, in 2008 by scientists from the Rudbeck Laboratory at Uppsala University together with Olink AB and the Uppsala University holding company, UUAB. We are an interdisciplinary, experienced and highly motivated team with state of the art development and manufacturing facilities based in the center of Uppsala Science Park. Q-linea is a privately held company developing inventive systems for in vitro diagnostics for infectious diseases.


The senior management provides experience from industrial development, as well as scientific and innovation start-up companies.

Jonas Jarvius

CEO & President of Q-linea AB, Dr. in Molecular Medicine, earlier an affiliated scientist at the Rudbeck Laboratory, Uppsala University. Co-founder of Olink AB and Q-linea AB, former CEO Sigolis.

During his PhD studies Dr. Jarvius focused at cross-disciplinary research at the boundaries of microfluidics and molecular medicine. Dr. Jarvius was one of the inventors and first author of the Amplified single molecule detection strategies used in Q-linea´s diagnostic and BW-agent detection platform. Dr. Jarvius is author of several scientific articles and book chapters, published in leading journals such as Nature Biotechnology, Nature Methods, Analytical Chemistry and Nucleic Acids Research. He is the designated inventor of several patents and patent applications.

Mats Gullberg

VP, Dr. in Medical Sciences, 2003, M.Sc in Pharmaceutical Microbiology, special focus microbial antibiotic resistance, 1995, both at Uppsala University, Sweden.

Co-founder and former CTO at Olink AB a Swedish company providing tools and reagents within protein biomarker analysis, with its spin-out companies Q-linea, Halo Genomics and Olink Proteomics. Named inventor of several patents and patent applications, including the granted patents on C2CA method and ASMD used by Q-linea. Close to 20 years' experience within biomedical research and transfer of scientific innovations into products as well as several years of experience of IP and licensing within the biotech sector.

Nils Kristensen

COO, has more than 20 years' experience in product and process development in conjunction with production implementation and operation.

Nils Kristensen has been working in both start-ups and fully industrial settings within the telecom and biotech tools fields. He has held multiple senior management positions, e.g. COO at Gyros AB, and is engaged in other start-up boards in Swedish high tech companies. Nils Kristensen has a formal background in Engineering Physics from Uppsala University.

Anders Lundin

CFO, over 20 years of experience in financial work and leadership in international organizations.

Anders Lundin is the founder and board member of CFO Akuten AB. Previous assignments include tf. CFO in Medivir AB (publ), Senior Financial Adviser and Controller in Sandvik Coromant Sverige AB, tf. CFO of BioPhausia AB, tf. and the regular CFO of Oasmia Pharmaceutical AB (publ) and Head and Finance in Q-Med AB, which since 2011 is a subsidiary of Galderma Pharma SA. Anders Lundin has a formal background as B.Sc. in Ba and Econ. from Uppsala University

Charlotta Göransson

Marketing Director, PhD in Molecular Medicine, has more than 15 years of experience in sales and marketing in Biotech Life Science.

Previously worked in companies such as Bio-Rad Laboratories, Olink AB and Denator AB, developing marketing strategies and organizing sales operations. Charlotta Göransson has a PhD in Molecular Medicine from Uppsala University focused on development of quantitative technologies for mutation detection.

Jonas Melin

Director Product Development, PhD in Engineering Physics, MSc in Engineering Biology

Jonas Melin has more than fifteen years’ experience from method development and the IVD industry. He was co-founder
and Chief Scientific Officer at Fiomi Diagnostics and has been project manager for several IVD product development projects, resulting in CE mark and FDA submission, including team leader at the System Development Department at Ortho-Clinical Diagnostics (a Johnson&Johnson Company). He was also one of the key persons in the development of one of Q-linea’s core technologies, amplified single-molecule detection and the designated inventor of several patents and patent applications.

Karl Sköld

Director Contract Development, PhD in Pharmaceutical Life Sciences, Uppsala University.

Karl Sköld has a background as researcher in molecular biology and pharmaceutical science at Uppsala University. Founder, board member and research director of Denator AB, and co-founder of Maurten AB. In 2017 he became CEO of Umbrella Science AB, whose business was acquired by Q-linea in the summer of 2018. Karl Sköld is also a board member of Hardcover AB, deputy board member of Laminaria Group AB and Maurten AB.

Board of Directors

Q-linea's BoD consist of a combination of entrepreneurs, inventors and industrial experienced persons representing the major owners of the company, and providing active support to the management.

Erika Kjellberg Eriksson

Chairman of the board

CEO of Nexttobe AB. Erika has been working in the life science sector for 15 years. Before joining Nexttobe, she served as CFO of OxThera, prior to that as Vice president and CFO of Q-Med and as CFO and CEO of BioPhausia. She has also been a board member of Bluefish Pharmaceuticals and A+ Science. Erika has a formal background as B.Sc. in Ba and Econ. from Uppsala University and started her career as an auditor at Ernst & Young.

Per-Olof Wallström

Board member

Per-Olof Wallström has 46 years of experience in the pharmaceutical and biotechnology industry and has held senior positions in Merck AB, Astra AB, Pharmacia AB and Bristol-Myers Squibb AB in the Nordic countries and Europe. He has also been CEO of Karo Bio AB, Melacure Therapeutics AB and Q-Med AB. Per-Olof Wallström is Chairman of Camurus AB and Camurus Development AB and Board member of Arosia Communication AB. Previous assignments include chairman of Nexttobe AB, AROSGRUPPEN Holding AB and Masmästaren Fjärdingen AB, NeoDynamics AB (publ), MB Eriksson Bygg & Fastighet AB, Chemilia AB, Aggal Invest AB and Patients Pending Ltd. Board member of Mediplast AB and Hansa Medical AB, as well as deputy board member of Addcode Design AB and Patients Pending AB.

Marianne Hansson

Board member

Marianne Hansson has 20 years experience in Life Science. She comes from a position as Chief Executive Officer at Atlas Antibodies AB and previously was Business Development Manager at Affibody Medical AB. She is co-founder of Affibody AB, Atlas Antibodies AB, ScandiBio Therapeutics AB, ScandiEdge Therapeutics AB and Amylonix AB. Marianne Hansson is a board member of Intervacc AB (publ) and Mariham Consulting AB, CEO of Mariham Consulting AB and external CEO of ScandiBio Therapeutics AB, ScandiEdge Therapeutics AB and Amylonix AB. Previous assignments include board member of Atlas Therapeutics AB, Deputy Board of Directors of Antibodies Incentive AB and external CEO of Atlas Antibodies AB.

Markus Storch

Board member

Former CEO of AGA AB. He is also the founder of the Tobias Foundation. Marcus Storch is Chairman of Kebris AB and Board member of Investment AB Öresund and Storch & Storch AB. Previous assignments include chairman of the Nobel Foundation and Board member of Nordstjernan AB, Axel Johnson AB, Mekonomen AB and Axfood AB.

Prof. Ulf Landegren

Board member

Co-founder of Olink AB and co-founder of ParAllele Bioscience Inc. Prof. Landegren is an internationally recognized scientific leader in molecular detection and amplification technologies, with an established network in the scientific and biotech business communities. Prof. Landegren has authored more than 200 peer-reviewed articles and is the designated inventor of more than 40 patents and patent applications. Developed molecular technologies include the oligonucleotide ligation assay (OLA), Padlock probes, Proximity ligation assays and Selector probes among others. A total of twelve internationally leading biotech or diagnostic companies have licensed technologies invented and reduced to practice by Professor Landegren’s lab, and from his lab eight biotech companies have emerged, three of which have been acquired by the public biotech companies Affymetrix, Agilent and PerkinElmer, while Olink Proteomics, Olink Bioscience, Genagon and Q-linea are still privately.

Prof. Mats Nilsson

Board member

Professor and Site director Science for Life Laboratory, Stockholm University, Sweden. Co-founder of Olink AB, Q-linea AB and ParAllele Bioscience Inc. Member of the board of ELOS AB and Olink AB. His research is focused on developing single-molecule and single-cell gene analytic techniques, employing advanced molecular tools combined with microscopy and microfluidics. Prof. Nilsson is author of more than 60 peer-reviewed articles, published in leading journals such as Science, Nature Genetics, Nature Biotechnology, Nature Methods, PNAS, Analytical Chemistry and Nucleic Acids Research. He is the designated inventor of 5 patents.

Hans Johansson

Board member

Hans Johansson has extensive experience and a broad network of contacts from previous roles in the Life Science and Diagnostics industry, lastly as Vice President, responsible for Companion Diagnostics, within the Thermo Fisher Speciality Diagnostics Group. Before that, Hans Johansson has been global marketing manager and responsible for marketing and commercial development within the Thermo Fisher Immuno Diagnostics Division and responsible for the Laboratory business area of ​​Pharmacia Biotechnology AB. Hans Johansson is Chairman of Myrtila AB and Doloradix AB, Board member of Uppsala Innovation Center AB, Immunovia AB (publ) and Single Technologies AB, as well as Deputy Board member of Duvbo Projektkonsult AB. Previous assignments include Deputy Board member in Duvbo Business Consultant AB.

Jon Heimer

Board member

Jon Heimer has 20 years of experience in developing and commercializing medical devices and pharmaceutical/biotech products. Jon has joined Q-linea's major owner, Nexttobe, from OxThera where he served as CEO since 2005, prior to that responsible for product and business development at Q-Med. Jon is an entrepreneur with a formal background in Economics from Uppsala University and Marketing from Eductus Business School in Sweden.